Technical Analysis for NLSP - NLS Pharmaceutics Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.23% | |
| Expansion Breakdown | Bearish Swing Setup | 0.23% | |
| Stochastic Buy Signal | Bullish | 0.23% | |
| Doji - Bullish? | Reversal | 0.23% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 14 hours ago |
| Up 3% | about 14 hours ago |
| Up 2% | about 14 hours ago |
| Up 1% | about 14 hours ago |
| Possible Inside Day | about 16 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neurological Disorders Psychiatric Diagnosis Psychiatry Sleep Disorders Attention Deficit Hyperactivity Disorder Drug Therapies Narcolepsy Amphetamine Methylphenidate Adhd Cataplexy Idiopathic Hypersomnia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neurological Disorders Psychiatric Diagnosis Psychiatry Sleep Disorders Attention Deficit Hyperactivity Disorder Drug Therapies Narcolepsy Amphetamine Methylphenidate Adhd Cataplexy Idiopathic Hypersomnia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.53 |
| 52 Week Low | 0.113 |
| Average Volume | 715,025 |
| 200-Day Moving Average | 0.58 |
| 50-Day Moving Average | 0.27 |
| 20-Day Moving Average | 0.15 |
| 10-Day Moving Average | 0.14 |
| Average True Range | 0.03 |
| RSI (14) | 24.24 |
| ADX | 21.73 |
| +DI | 11.85 |
| -DI | 23.41 |
| Chandelier Exit (Long, 3 ATRs) | 0.11 |
| Chandelier Exit (Short, 3 ATRs) | 0.19 |
| Upper Bollinger Bands | 0.18 |
| Lower Bollinger Band | 0.12 |
| Percent B (%b) | 0.19 |
| BandWidth | 42.61 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0067 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.16 | ||||
| Resistance 3 (R3) | 0.16 | 0.15 | 0.15 | ||
| Resistance 2 (R2) | 0.15 | 0.14 | 0.15 | 0.15 | |
| Resistance 1 (R1) | 0.14 | 0.13 | 0.14 | 0.14 | 0.15 |
| Pivot Point | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
| Support 1 (S1) | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| Support 2 (S2) | 0.11 | 0.12 | 0.11 | 0.11 | |
| Support 3 (S3) | 0.10 | 0.11 | 0.11 | ||
| Support 4 (S4) | 0.10 |
